RxDoctor Payments Data

Ok Park, MD

Ophthalmology · Baltimore, MDNPI 1659306520

Payments from drug & device makers

$711in general payments, 2019–2025

Across 26 payments — averaging $27.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$172
  • Tarsus Pharmaceuticals, Inc.$135
  • Oyster Point Pharma, Inc.$118
  • Alcon$78
  • Sun Pharmaceutical Industries Inc.$72
  • Bausch & Lomb Americas Inc.$47
  • plus $89 from 3 others

What the payments were for

  • Food & beverage$711100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$711 in reported general payments places this provider in the 35th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$228,634
Medicare patients
940
Services billed
2,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine65$94,278
LumiganBimatoprost115$77,861
RocklatanNetarsudil Mesylat/Latanoprost49$38,442
VyzultaLatanoprostene Bunod53$29,228
Cyclosporine44$18,439
CombiganBrimonidine Tartrate/Timolol27$14,219
Latanoprost615$9,963
SimbrinzaBrinzolamide/Brimonidine Tart31$9,694
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$4,930
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat214$4,785
Travoprost24$4,315
Timolol Maleate159$3,621
Prednisolone Acetate82$3,290
Dorzolamide-TimololDorzolamide/Timolol/Pf12$3,223
Brimonidine Tartrate211$2,392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$172$186,358207 claims
Aerie Pharmaceuticals, Inc.Rocklatan$36$38,44249 claims
Bausch & Lomb Americas Inc.Vyzulta$47$29,22853 claims
AlconSimbrinza$78$9,69431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →